6 terminated, 4 completed, 2 active not recruiting, 2 unknown. 17 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 6, Completed 4, Active not recruiting 2, Unknown 2, Withdrawn 2, Recruiting 1 |
| Phase 1 | 5 | Terminated 2, Unknown 2, Recruiting 1 |
Follow AZD2014: new trials by email Literature Review of AZD2014 trials Research Report on AZD2014
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2018-03-20 | 2023-10-17 |
| Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy Vistusertib(AZD2014) - Solid Tumor | Phase 2 | Withdrawn | Samsung Medical Center | 2018-03-01 | 2019-05-20 | |
| Phase II Trial of Vistusertib(AZD2014) Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy Vistusertib(AZD2014) - Solid Tumor | Phase 2 | Withdrawn | Samsung Medical Center | 2018-03-01 | 2019-05-20 | |
| Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas AZD2014 - Meningioma | Phase 2 | Active not recruiting | Massachusetts General Hospital | 28 | 2017-10-17 | 2022-10-18 |
| A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies acalabrutinib, vistusertib - DLBCL, Richter Syndrome | Phase 1 / Phase 2 | Terminated | Acerta Pharma BV | 25 | 2017-06-29 | 2021-01-06 |
| Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy AZD2014 - Stomach Neoplasms | Phase 2 | Terminated | Samsung Medical Center | 1 | 2017-02-01 | 2019-05-20 |
| Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy AZD2014 - Cancer of Stomach | Phase 2 | Terminated | Samsung Medical Center | 1 | 2017-02-01 | 2019-05-20 |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas AZD2014 - Neurofibromatosis 2, Meningioma | Phase 2 | Completed | Massachusetts General Hospital | 18 | 2016-08-31 | 2022-06-13 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) AZD2014, Anastrozole - Endometrial Carcinoma, Metastatic Carcinoma | Phase 1 / Phase 2 | Unknown | Centre Leon Berard | 72 | 2016-04-01 | 2024-02-13 |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers AZD2014, AZD6244 - Triple-Negative Breast Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Queen Mary University of London | 118 | 2015-06-01 | 2020-02-25 |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer AZD4547, Vistusertib, Palbociclib - Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell | Phase 2 | Completed | University of Birmingham | 423 | 2015-05-13 | 2026-04-28 |
| Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy AZD5363, paclitaxel, AZD2014 - Advanced Gastric Adenocarcinoma | Phase 2 | Terminated | Samsung Medical Center | 27 | 2015-02-12 | 2019-05-20 |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients AZD2014, AZD4547, AZD5363 - Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | UNICANCER | 999 | 2014-04-23 | 2024-01-10 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer | Phase 2 | Active not recruiting | UNICANCER | 1460 | 2014-04-07 | 2025-01-15 |
| A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer AZD2014, Everolimus, Fulvestrant - Estrogen Receptor Positive Breast Cancer | Phase 2 | Completed | Queen Mary University of London | 333 | 2014-01-16 | 2024-12-02 |
| A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer AZD2014, Everolimus - Metastatic Clear Cell Renal Carcinoma | Phase 2 | Terminated | Queen Mary University of London | 49 | 2013-02-01 | 2014-06-24 |
Meningioma (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neurofibromatosis 2 (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Samsung Medical Center (5) · Queen Mary University of London (3) · Massachusetts General Hospital (2) · UNICANCER (2) · Acerta Pharma BV (1) · Centre Leon Berard (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · National Cancer Institute (NCI) (1) · University of Birmingham (1)
South Korea (6) · United Kingdom (6) · France (5) · United States (4) · Spain (2) · Denmark (1) · Georgia (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Portugal (1) · Romania (1)
Birgit Geoerger, MD (1) · Christine L Hann (1) · Gary W Middleton (1) · Jeeyun Lee, Md,PhD (1) · Peter Schmid, Prof (1) · Peter Schmid, Professor (1) · Scott Plotkin, MD, PhD (1) · Scott R. Plotkin, MD, PhD (1) · Thomas Powles (1)
PMID 26410619, PMID 31465093, PMID 31538815, PMID 32067679, PMID 32669708, PMID 33892407, PMID 34269152, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35551299, PMID 39998620, PMID 40069402, PMID 41838385, PMID 42686334
2014 (2), 2016 (1), R01CA201130 (1), UM1CA186691 (1)